Show simple item record

dc.contributor.authorAaseth, Eirik
dc.contributor.authorChristiansen, Jon Runar
dc.date.accessioned2024-11-15T13:25:09Z
dc.date.available2024-11-15T13:25:09Z
dc.date.created2024-01-25T13:46:35Z
dc.date.issued2024
dc.identifier.citationESC Heart Failure. 2024, 11 (2), 871-876.en_US
dc.identifier.issn2055-5822
dc.identifier.urihttps://hdl.handle.net/11250/3165208
dc.description.abstractAims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by increased wall thickness, diastolic dysfunction and progressive heart failure symptoms. The disease may infiltrate the conduction system leading to conduction disturbances requiring an implantation of permanent cardiac pacemaker (PM), but the extent is unknown. Here, we report the prevalence of ATTR-CM in patients ≥65 years with PM. Methods and results: In this prospective, cross-sectional single-centre study patients were recruited from our out-patient pacemaker clinic. Eligibility criteria were age above 65 years, permanent cardiac pacemaker and competent to give informed consent. Patients underwent echocardiography at the pacemaker visit and were referred to 99mTc-DPD-scintigraphy (DPD) and blood samples if septum thickness was ≥12 mm, defined as left ventricular hypertrophy (LVH). Fifty eight of the 128 patients had LVH on echocardiography. Eleven patients had a DPD-scintigraphy based diagnosis of ATTR-CM, which represent 19% of patients with LVH and 9% of the total cohort. Patients diagnosed with ATTR-CM had higher concentrations of cardiac biomarkers (P < 0.001), higher E/E' (P = 0.001), and lower global longitudinal strain (P = 0.003) on echocardiography and more heart failure symptoms (P = 0.001). Conclusions: The prevalence of ATTR-CM in elderly patients with PM and LVH on echocardiography was 19%.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.urihttps://onlinelibrary.wiley.com/doi/10.1002/ehf2.14645
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.subjectCardiac amyloidosisen_US
dc.subjectLeft ventricular hypertrophyen_US
dc.subjectPermanent cardiac pacemakeren_US
dc.subjectTransthyretin amyloid cardiomyopathyen_US
dc.titlePrevalence of transthyretin amyloid cardiomyopathy in pacemaker patientsen_US
dc.title.alternativePrevalence of transthyretin amyloid cardiomyopathy in pacemaker patientsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.en_US
dc.source.pagenumber871-876en_US
dc.source.volume11en_US
dc.source.journalESC Heart Failureen_US
dc.source.issue2en_US
dc.identifier.doi10.1002/ehf2.14645
dc.identifier.cristin2234494
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal